Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 8,000 Shares of Stock

Key Points

• Director Robert Glassman sold 8,000 Pharvaris shares at an average price of $37.55, generating $300,400 and reducing his position by 43.24% to 10,500 shares.
• Pharvaris reported that once-daily extended-release deucrictibant reduced hereditary angioedema attack rates by 83% versus placebo in its Phase 3 CHAPTER-3 trial, supporting planned regulatory applications beginning in the first half of 2027.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and an average price target of $59.50, though the clinical-stage company continues to face regulatory, competitive, execution, and operating-loss risks.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) Director Robert Glassman sold 8,000 shares of the company's stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $37.55, for a total transaction of $300,400.00. Following the completion of the sale, the director owned 10,500 shares of the company's stock, valued at approximately $394,275. The trade was a 43.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pharvaris Stock Performance

PHVS traded up $0.69 during midday trading on Friday, reaching $38.20. The company had a trading volume of 838,126 shares, compared to its average volume of 389,200. The stock has a market cap of $2.50 billion, a PE ratio of -12.45 and a beta of -2.33. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25. The business has a 50-day moving average price of $35.01 and a two-hundred day moving average price of $31.34.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). On average, research analysts anticipate that Pharvaris N.V. will post -3.1 earnings per share for the current year.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the company said the data supported all primary and secondary efficacy endpoints. Regulatory applications are planned to begin in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The CHAPTER-3 results, together with earlier positive data for on-demand deucrictibant, strengthen Pharvaris’ potential to offer convenient oral treatments for both prevention and acute treatment of HAE attacks. Analysts believe the oral formulation could help the company gain market share. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment strengthened: Leerink Partners initiated or reiterated a Buy with a $65 price target, RBC Capital raised its target to $62 while maintaining a Buy rating, and Citizens JMP lifted its target to $79 with a Market Outperform rating. HC Wainwright also maintained a Buy rating with a $60 target, reinforcing expectations for substantial upside if development and regulatory plans remain on track.
• Neutral Sentiment: Pharvaris remains a clinical-stage biotechnology company with no approved commercial product. Regulatory review, launch execution, competition from existing HAE therapies, and continued operating losses remain key risks.
• Negative Sentiment: President Peng Lu sold 15,000 shares for approximately $610,200, reducing his direct ownership by 18.71%. The sale may create a modest insider-selling overhang, although it does not alter the favorable clinical data.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System lifted its position in Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company's stock valued at $666,000 after purchasing an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after buying an additional 783 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Pharvaris during the 2nd quarter valued at $41,000. Public Employees Retirement System of Ohio raised its position in shares of Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company's stock valued at $210,000 after buying an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company's stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter.

Analyst Ratings Changes

Several research firms have commented on PHVS. Wedbush set a $50.00 price objective on shares of Pharvaris and gave the company an "outperform" rating in a report on Wednesday. Wells Fargo & Company lifted their target price on shares of Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research note on Wednesday. Wall Street Zen lowered shares of Pharvaris from a "hold" rating to a "sell" rating in a research report on Saturday, July 18th. Royal Bank Of Canada raised their price objective on shares of Pharvaris from $52.00 to $62.00 and gave the stock an "outperform" rating in a report on Wednesday. Finally, UBS Group set a $79.00 target price on shares of Pharvaris in a report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pharvaris has a consensus rating of "Moderate Buy" and an average price target of $59.50.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.